Bluejay Diagnostics, Inc.

30 articles about Bluejay Diagnostics, Inc.

• Bluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial Results

  11/9/2023

  Bluejay Diagnostics, Inc. reported its financial results for the quarter and nine months ended September 30, 2023.

• Bluejay Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement

  8/10/2023

  Bluejay Diagnostics, Inc. announced that on August 8, 2023, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that it had regained compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rule 5550.

• Bluejay Diagnostics Updates Symphony IL-6 Regulatory Strategy

  5/19/2023

  Bluejay Diagnostics, Inc. today announced an updated clinical and regulatory strategy for the Symphony IL-6 biomarker test to measure acuity in sepsis patients.

• Bluejay Diagnostics Reports First Quarter 2023 Financial Results

  5/10/2023

  Bluejay Diagnostics, Inc. today announced financial results for the quarter ended March 31, 2023.

• Bluejay Diagnostics Reports 2022 Financial Results

  3/20/2023

  Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid tests using whole blood on its Symphony platform to improve patient outcomes in critical care settings, today reported its financial results for the year ended December 31, 2022.

• Bluejay Diagnostics Signs Collaboration Agreement with Blood Centers of America

  2/16/2023

  Bluejay Diagnostics, Inc., and Blood Centers of America announced that they have executed a collaborative agreement to develop commercial relationships to serve unmet needs by utilizing the SymphonyTM Platform in the blood and hospital markets.

• Bluejay Diagnostics, Inc. Reports Third Quarter 2022 Financial Results

  11/9/2022

  Bluejay Diagnostics, Inc. reported its financial results for the quarter and nine months ended September 30, 2022.

• Bluejay Diagnostics, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

  8/30/2022

  Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient tests for triage and monitoring of disease progression, today announced that Neil Dey, Chief Executive Officer, and Kenneth Fisher, Chief Financial Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference.

• 

  Money on the Move: AdvanCell, eTheRNA, Bluejay and More

  8/24/2022

  ​​​​​​​Money is now flowing into promising platforms for prostate cancer from AdvanCell, mRNA therapeutics from eTheRNA, hepatitis from Bluejay and more.

• Bluejay Diagnostics, Inc. to Host Key Opinion Leader Event on IL-6 Testing in Critical Care Settings: The Emerging Use of Biomarkers in Contemporary Management of COVID-19/Respiratory Failure

  8/16/2022

  Bluejay Diagnostics, Inc. today announced that it will hold a virtual Key Opinion Leader (KOL) event on IL-6 Testing in Critical Care Settings.

• Positive Clinical Results for Bluejay’s Symphony IL-6 Test Presented at AACC 2022

  7/27/2022

  Bluejay Diagnostics, Inc. today announced that positive results of analytical and clinical studies of Bluejay’s Symphony IL-6 Test were presented at AACC 2022, the leading industry conference for clinical laboratory medicine.

• Bluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results

  7/26/2022

  Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient tests for triage and monitoring of disease progression, today announced financial results for the quarter and six months ended June 30, 2022.

• Bluejay Completes Planned Clinical Studies for Symphony IL-6 Test

  7/6/2022

  Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced completion of its previously planned clinical studies for the Symphony IL-6 Test (the “Test”). Results of these studies will be published at the 2022 AACC Annual Scientific Meeting being held July 26th to 28th in Chicago.

• Bluejay Reports FDA Agrees to Consider its Plan to Pursue a De Novo Regulatory Pathway for the Symphony IL-6 Test

  6/9/2022

  Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression , today announced that the FDA has agreed to consider Bluejay’s plan to pursue a De Novo submission for the Symphony IL-6 Test.

• Bluejay Diagnostics, Inc. Reports First Quarter 2022 Financial Results

  4/20/2022

  Bluejay Diagnostics, Inc. today announced financial results for the quarter ended March 31, 2022.

• 

  BioSpace Movers & Shakers, April 1

  4/1/2022

  It's a new month and a new chapter for several life sciences executives. Here's a look at some notable Movers & Shakers beginning April with new companies. 

• Bluejay Diagnostics Appoints Edwin Rule as Vice President, Regulatory, Quality and Compliance

  3/28/2022

  Bluejay Diagnostics, Inc. today announced that Edwin “Ed” E. Rule, has joined the Company as Vice President Regulatory, Quality and Compliance. He will report to Neil Dey, Chief Executive Officer.

• 

  BioSpace Movers & Shakers, March 25

  3/25/2022

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Bluejay Diagnostics Appoints Kenneth Fisher as Chief Financial Officer

  3/24/2022

  Bluejay Diagnostics, Inc., a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, announced that Kenneth Fisher, CPA, has joined the Company as Chief Financial Officer, effective March 23, 2022.

• Bluejay Diagnostics, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

  3/10/2022

  Bluejay Diagnostics, Inc. announced financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update, including on the Company’s first product candidate, the IL-6 Test.